Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

200.10 -2.53 (-1.25%)
Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
Lost Money on Moderna, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 23.07% Share Price Drop
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Did You Lose Money on Moderna, Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 23.07% Share Price Decline
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Moderna Named a Top Employer by Science for Twelfth Consecutive Year
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Lost Money on Moderna, Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 23.07% Stock Decline
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
From Merck & Co., Inc.
Via Business Wire
News headline image
AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test
From Biotech Insider
Via GlobeNewswire
News headline image
Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Adds Chief Operating Officer Role as Company Expands into Oncology
Juan Andres to Return to Moderna as Chief Operating Officer Jerh Collins to Retire Following Four Years of Leadership at Moderna 
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected for presentation at a Presidential Symposium Moderna to host an investor event... 
From Moderna, Inc.
Via ACCESS Newswire
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:GILD),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:BNTX) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Moderna to Present at Upcoming Conferences in September 2026
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes
From Moderna, Inc.
Via ACCESS Newswire
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:BNTX),(NYSE:AZN),(NASDAQ:MRNA),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
A New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision Oncology 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Appoints Michael McDonnell to Board of Directors
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Science Day Highlights Expanding Potential of mRNA Platform
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna to Host Investor Event - Science Day
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
Via ACCESS Newswire
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
Via Investor Brand Network
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.